TriangleFicerafusp alfa (NCT07807163)
Ficerafusp alfa trial for Metastatic Head and Neck Squamous Cell Carcinoma (NCT07807163). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with recurrent or metastatic, PD-L1-positive squamous cancer of the oral cavity, hypopharynx, larynx or HPV-negative oropharynx. No systemic treatment for recurrence or metastasis is allowed; curative local treatment must be unsuitable.
The idea: ficerafusp targets EGFR and TGF-beta; pembrolizumab blocks PD-1 immune suppression. Everyone starts twelve weeks of weekly ficerafusp plus pembrolizumab every three weeks. Patients without progression then enter randomized maintenance with weekly or three-weekly ficerafusp, continuing pembrolizumab. Researchers assess progression-free survival.
This phase 2 study plans 160 patients. Bicara Therapeutics sponsors seven recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.